Notes on Psychotherapeutic Agents (Antipsychotics and Lithium)

Overview of Psychotherapeutic Agents

  • Used to treat psychoses (perceptual and behavioral disorders).

  • These medications help patients function more normally and perform activities of daily living, but they do not cure the disorder.

  • They are used across the lifespan (children, adults, older adults).

Conditions Treated and General Considerations

  • Schizophrenia: most common mental disorder; symptoms include hallucinations, paranoia, delusions, speech abnormalities, and social withdrawal; may have a genetic component and biochemical abnormalities.

  • Bipolar disorder: extreme depression followed by hyperactivity/excitement; strong genetic component; biochemical imbalance with neuronal overcompensation and instability in the brain.

  • In children: these medications are used, often in combination with other CNS drugs; long-term effects are not fully known; careful monitoring of adverse effects and developmental progress.

  • Lithium use in children is typically avoided; if used, close monitoring of lithium levels is required.

  • Treatment with psychotherapeutic agents should be part of an interdisciplinary approach.

  • Adults should have regular follow-up with providers to monitor therapy.

Lifespan, Safety, and Monitoring Considerations

  • Some antipsychotics carry a risk of prolonged QT interval, increasing risk of fatal arrhythmias; an EKG is needed before initiation for those meds.

  • These drugs should be used with caution during pregnancy and lactation.

  • Lithium: risk of serious congenital abnormalities; barrier contraception advised for women of childbearing age.

  • Older adults: more susceptible to adverse effects; may require reduced doses and closer monitoring for toxic effects; safety measures needed for CNS effects.

  • Antipsychotics with dementia-related psychosis: increased risk of death; black box warning; use with caution in this population.

  • Renal impairment with lithium requires dose monitoring; hydration and salt (sodium) intake are important, as dehydration or hyponatremia increases lithium reabsorption and toxicity risk.

  • QT prolongation monitoring remains important in older adults and those with heart disease.

Antipsychotic Drugs: Classes and Mechanisms

  • Antipsychotics are divided into typical (first-generation) and atypical (second-generation) agents.

  • Typical antipsychotics: primarily block dopamine receptors.

  • Atypical antipsychotics: block both dopamine and serotonin receptors; provide added benefit of seratonin blockade which can help prevent depression and some neurological adverse effects.

  • Mechanistic summary:

    • Typical: dopamine receptor blockade reduces psychotic symptoms.

    • Atypical: dopamine and serotonin receptor blockade; may reduce depressive symptoms and some extrapyramidal effects.

  • Pharmacokinetics note: for antipsychotics, the intramuscular dose can be up to about five times the active oral dose (IM typically requires a much lower dose than PO).

  • Absolute contraindication: allergy.

  • Relative contraindications include CNS depression, hematologic disorders (blood dyscrasias), Parkinson’s disease progression, prolonged QT interval, glaucoma, urinary retention, seizure disorder, hepatic/renal/cardiac disease.

  • Important safety concept: black box warning for increased mortality in elderly patients with dementia-related psychosis.

  • Additional cautions: anticholinergic effects can worsen glaucoma, urinary retention, military hypertrophy, or cause other urinary/GI issues; monitor for seizure threshold changes.

Specific Antipsychotics

  • Typical antipsychotics (end in -zine):

    • Prochlorperazine

    • Thioridazine

    • Chlorpromazine (often misspelled as clopromazine in notes)

    • Haloperidol (noted as an outlier in some lists)

  • Atypical antipsychotics (dopamine and serotonin receptor blockade):

    • Aripiprazole (also listed as pipelines like "piprazole" in some transcripts)

    • Brexpiprazole

    • Quetiapine

    • Olanzapine

    • Clozapine

    • Risperidone

    • Ziprasidone

    • Iloperidone

  • Mechanistic takeaway: Typical agents block dopamine receptors (RAS and broader CNS networks); atypical agents block both dopamine and serotonin receptors, with added antidepressant-like benefits.

  • Reticular activating system (RAS) note: a diffuse brainstem network that influences alertness and consciousness; dopamine blockade can affect alertness and motor function.

Pharmacokinetics, Dosing, and Contraindications

  • Administration and dosing:

    • IM dose can be up to ~5x the oral dose due to pharmacokinetic differences.

    • Absolute contraindication: allergy.

    • Relative contraindications: CNS depression, blood dyscrasias, Parkinson’s disease, prolonged QT, glaucoma, urinary retention, seizure disorders, hepatic/renal/cardiac disease.

  • Adverse effects are related to dopamine blockade, anticholinergic, antihistaminergic, and antiadrenergic effects.

  • Common CNS effects: drowsiness, sedation, weakness, tremors.

  • Extrapyramidal symptoms (EPS):

    • Pseudo-Parkinsonism (drooling, shuffling gait)

    • Dystonia (tongue, neck, back muscle spasms)

    • Akathisia (continuous restlessness)

    • Tardive dyskinesia (involuntary movements, e.g., lip smacking)

  • Neuroleptic Malignant Syndrome (NMS): high fever, muscle rigidity, dysautonomia; potentially irreversible; treat with supportive care and discontinue offending drug; manage blood pressure, body temperature, and muscle rigidity.

  • Anticholinergic effects: constipation, dry mouth, blurred vision, nasal congestion, urinary retention.

  • Other adverse effects: gynecomastia, prolonged QT, hypotension, orthostatic hypotension, bone marrow suppression (decreased RBC/platelets/WBC).

  • Metabolic concerns: long-term atypicals can cause diabetes and weight gain; interactions with CNS depressants (e.g., alcohol) and anticholinergics can worsen CNS and anticholinergic effects.

  • Lifespan considerations:

    • Elderly: greater sensitivity to adverse effects; closer monitoring and dose adjustments.

    • Dementia-related psychosis: increased mortality risk; need for cautious use.

  • Drug interactions:

    • CNS depressants (including alcohol) can enhance CNS effects.

    • Anticholinergic drugs can worsen anticholinergic burden.

    • Lithium interactions (see lithium section) and other CNS-active drugs.

Nursing Process for Antipsychotics

  • Assessment

    • History of cautions/contraindications: allergies, severe CNS depression, brain damage, respiratory depression, coronary or cardiac disease with prolonged QT, hypotension, glaucoma, urinary retention, bone marrow suppression.

    • Physical exam: vital signs, CNS status (orientation/affect), cardiac status (EKG if indicated), abdominal GI status, etc.

    • Lab tests: renal and hepatic function; CBC (bone marrow suppression risk); CVC (bone marrow suppression risk is conceptually covered here).

  • Nursing Diagnoses (typical examples):

    • Impaired physical mobility related to extrapyramidal effects

    • Altered cardiac output related to hypotensive effects and prolonged QT risk

    • Fall risk and risk for injury related to CNS effects and sedation

    • Impaired urinary elimination related to anticholinergic effects

    • Constipation related to anticholinergic effects

    • Knowledge deficit regarding drug therapy

  • Implementation (administration and safety):

    • For parenteral administration, keep patient recumbent for ~30 minutes to reduce orthostatic hypotension risk.

    • Monitor CBC for bone marrow suppression; monitor glucose for glucose intolerance.

    • Gradual dose reduction after long-term use; avoid abrupt withdrawal to prevent adverse effects.

    • Assist with positioning to minimize dyskinesia-related discomfort.

    • For dry mouth, offer sugarless lozenges or ice chips.

    • For urinary retention risk, encourage voiding before dosing when appropriate.

    • Safety measures for CNS effects or orthostatic hypotension (fall precautions).

    • Eye/vision changes: arrange visual exams as needed.

    • Provide comprehensive patient teaching on adverse effects and coping strategies; warn about risks of tardive dyskinesia, NMS, EPS; instruct to report changes immediately.

    • Explain that effects may take weeks to become evident; continue therapy even if no immediate improvement; pink-to-reddish-brown urine color can occur with some drugs—explain this to reduce patient concern.

  • Evaluation of antipsychotics

    • Assess drug response: reduction in psychotic signs/symptoms.

    • Monitor for adverse effects: sedation, anticholinergic effects, hypotension, EPS, NMS, bone marrow suppression, glucose intolerance.

    • Assess effectiveness of teaching plan: patient can name the drug, dosing schedule, and adverse effects; assess adherence.

  • What to report to provider

    • Effectiveness of comfort/safety measures, patient compliance, any adverse effects observed, and overall response to therapy.

Antipsychotics in Bipolar Disorder and Other Agents

  • Bipolar disorder treatment often includes Lithium as the mainstay, with adjunctive agents such as some antipsychotics (e.g., aripiprazole, quetiapine) and anticonvulsants used as alternatives.

  • We also use some anti-seizure medications in bipolar treatment; those specifics are covered in separate chapters.

Lithium in Bipolar Disorder: Mechanism, Monitoring, and Safety

  • Lithium is a primary mood stabilizer for bipolar disorder; other meds include aripiprazole, quetiapine, and ziprasidone; anticonvulsants are used in some cases.

  • Mechanism: Lithium alters sodium transport in nerve and muscle cells and influences reuptake of dopamine and norepinephrine; exact mechanism for mania control is not fully understood.

  • Pharmacokinetics and Therapeutic Range:

    • Therapeutically effective serum level: 0.6≤[Li+]≤1.2 mEq/L0.6 \le [Li^+] \le 1.2 \text{ mEq/L}

    • Toxicity risk increases with levels above therapeutic range; dehydration and hyponatremia increase lithium reabsorption in the kidneys, raising toxicity risk.

  • Contraindications:

    • Absolute: allergy.

    • Relative: significant renal or cardiac disease; dehydration or sodium depletion; diuretic use; pregnancy; lactation; dehydration risk factors.

  • Adverse effects (LITH mnemonic):

    • L: Leukocytosis

    • I: Insipidus (diabetes insipidus) – excessive thirst and urination due to reduced ADH response

    • T: Tremors

    • H: Hypothyroidism or Hyperthyroidism (lithium acts like iodine; can suppress or stimulate thyroid function)

    • Additional notes: teratogenic effects; risk of thyroid dysfunction requiring monitoring.

  • Toxicity and level-specific effects:

    • Mild elevations: lethargy, slurred speech, fatigue, GI disturbances.

    • 2.0–2.5: ataxia, clonic movements, hyperreflexia, seizures.

    • >2.5: complex multiorgan toxicity with substantial risk of death.

  • Drug interactions:

    • Haloperidol (antipsychotic): increases risk of encephalopathy.

    • Carbamazepine: increases CNS toxicity.

    • Diuretics: increase lithium toxicity due to sodium loss and enhanced reabsorption of lithium.

    • Psyllium: reduces absorption of lithium, potentially lowering therapeutic levels.

  • Assessment for lithium therapy:

    • History of allergy, renal or cardiovascular disease, dehydration or sodium depletion, diuretic use, any febrile illness or illnesses causing vomiting/diarrhea.

    • Pregnancy or lactation status.

  • Physical exam and labs:

    • Vital signs; temperature (fever → dehydration risk).

    • Skin turgor and mucous membranes (dehydration assessment).

    • CNS status (orientation/affect).

    • Abdominal exam (GI effects are early signs of toxicity).

    • Urine output monitoring (dehydration indicator).

    • Labs: renal function; CBC (leukocytosis risk); thyroid function; lithium level; sodium level; possibly EKG for cardiac monitoring.

  • Nursing conclusions and diagnoses:

    • Acute pain related to GI and CNS effects

    • Risk for injury related to CNS effects

    • Impaired urinary elimination related to renal toxicity effects

    • Disturbed thought processes related to CNS effects

    • Deficient knowledge regarding drug therapy

  • Implementation and monitoring strategies:

    • Monitor serum lithium levels frequently: at therapy initiation (e.g., every 2–3 days) until stable, then every 3–6 months; patients with renal/cardiovascular disease, dehydration, or diuretic use may require even more frequent monitoring (potentially daily).

    • Administer with food or milk to minimize GI effects.

    • Initiate dose reductions after an acute manic episode as mania improves to prevent toxicity during maintenance.

    • Monitor clinical status closely to ensure levels remain in the therapeutic range and to detect adverse effects early.

    • Manage GI upset with small, frequent meals; offer sugarless lozenges for dry mouth; maintain oral hygiene.

    • Implement safety precautions for CNS effects to prevent injury; provide patient safety education.

    • Provide thorough patient education on adverse effects, warning signs requiring provider notification, the importance of follow-up and lab monitoring, and pregnancy precautions.

    • Emphasize dehydration prevention, especially in hot weather, illness, or exercise; ensure adequate hydration and salt intake.

  • Evaluation of lithium therapy and teaching:

    • Assess response: reduction in manic symptoms and frequency of episodes.

    • Monitor for adverse effects: cardiovascular toxicity, renal toxicity, GI upset, CNS effects, etc.

    • Evaluate the effectiveness of teaching: patient understanding of drug, dosing, timing, follow-up, adverse effects, and when to contact the provider.

  • Practical patient education points to convey:

    • Expect gradual improvement; abrupt cessation should be avoided.

    • Some patients may notice pinkish to reddish-brown urine color; explain this can occur with some meds and is not always dangerous, but warrants evaluation if persistent or accompanied by other symptoms.

    • Ensure adherence and schedule follow-ups; discuss hydration and salt intake; discuss signs of toxicity and when to seek care.

Key Formulas, Ranges, and Numerical References (for quick study)

  • Lithium therapeutic range: 0.6≤[Li+]≤1.2 mEq/L0.6 \le [Li^+] \le 1.2 \text{ mEq/L}

  • Lithium toxicity: mild elevations lead to lethargy, slurred speech, GI symptoms; 2.0–2.5 \text{mEq/L} \rightarrow ataxia, clonic movements, hyperreflexia, seizures; >2.5 \text{mEq/L} \rightarrow multiorgan toxicity and risk of death.

  • Antipsychotic dosing note: IM dose up to about five times the active oral dose.

  • Drug interactions:

    • Haloperidol + lithium ⇒ encephalopathy risk increases

    • Carbamazepine ⇒ increased CNS toxicity

    • Diuretics ⇒ increased lithium toxicity due to sodium loss

    • Psyllium ⇒ decreased lithium absorption, potentially reducing therapeutic levels

  • The dopamine blockade and receptor targets:

    • Typical antipsychotics block dopamine receptors (RAS involved in consciousness)

    • Atypical antipsychotics block dopamine and serotonin receptors

Connections to Foundations and Real-World Relevance

  • Interdisciplinary care is essential: psychiatry, primary care, nursing, social work, and family/caregiver support impact outcomes.

  • Understanding drug mechanisms helps predict efficacy and adverse effects, guiding monitoring and patient education.

  • Safety considerations (QT prolongation, cardiovascular risk, falls, metabolic syndrome) have real-world implications for prescribing in older adults and those with comorbidities.

  • Ethical considerations include ensuring informed consent, discussing risks with patients and families, and balancing symptom control with quality of life, particularly in dementia-related cases and pregnancy planning.